Product Information
FINACEA 15% FOAM is a brand product labeled by LEO Pharma Inc., priced at $8.3337 per GM under NDC 50222030350. Its NADAC has been published 331 times since Jun 3, 2020.
FDA first approved this application on Jul 29, 2015.
The High Outlier badge above means this manufacturer's average price in the azelaic acid market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
.15 g/g
Manufacturer
LEO Pharma Inc.NDC
50222030350
Classification
Brand
Dosage Form
AEROSOL, FOAM
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
AZELAIC ACIDApproval Type
New Drug (NDA)
FDA Application
NDA207071FDA Approved
7/29/2015
On Market Since
10/1/2018
Pharmacological Classes
Price Statistics
The NADAC for FINACEA 15% FOAM has been published 331 times since Jun 3, 2020, and over the history we have for it it has risen 18.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.3337 per GM |
|---|---|
| All-time high | $8.3772 (Sep 11, 2024) |
| All-time low | $6.9701 (Jul 22, 2020) |
| 52-week high | $8.3394 |
| 52-week low | $8.3224 |
| Median price | $8.1213 |
| Average price | $7.9096 |
| Largest weekly change | +6.0% (Jan 18, 2023) |
| Weeks tracked | 331 |
| Tracking since | Jun 3, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the azelaic acid market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
LEO Pharma Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
azelaic acid market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of FINACEA 15% FOAM?
The current National Average Drug Acquisition Cost (NADAC) for FINACEA 15% FOAM, manufactured by LEO Pharma Inc., is $8.3337 per GM (NDC 50222030350), effective Sep 30, 2026.
How has the price of FINACEA 15% FOAM changed over time?
Over the history we have for it, the NADAC for FINACEA 15% FOAM has risen 18.9%. It has been tracked across 331 weekly CMS publications since Jun 3, 2020.
What are the highest and lowest recorded NADAC prices for FINACEA 15% FOAM?
Since Jun 3, 2020, the NADAC for FINACEA 15% FOAM has ranged from a low of $6.9701 (Jul 22, 2020) to a high of $8.3772 (Sep 11, 2024), with a median of $8.1213 per GM.
Are there cheaper alternatives to FINACEA 15% FOAM?
No other NADAC-published product currently shares the active ingredient and strength of FINACEA 15% FOAM in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures FINACEA 15% FOAM?
FINACEA 15% FOAM (NDC 50222030350) is labeled by LEO Pharma Inc., and CMS classifies it as a brand product.